See more : TechCom, Inc. (TCRI) Income Statement Analysis – Financial Results
Complete financial analysis of JCR Pharmaceuticals Co., Ltd. (4552.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of JCR Pharmaceuticals Co., Ltd., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- EGLS Co.,Ltd. (002619.SZ) Income Statement Analysis – Financial Results
- Bonava AB (publ) (BONAV-B.ST) Income Statement Analysis – Financial Results
- Batliboi Limited (BATLIBOI.BO) Income Statement Analysis – Financial Results
- K.M. Sugar Mills Limited (KMSUGAR.BO) Income Statement Analysis – Financial Results
- Andretti Acquisition Corp. (WNNR) Income Statement Analysis – Financial Results
JCR Pharmaceuticals Co., Ltd. (4552.T)
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.87B | 34.34B | 51.08B | 30.09B | 24.78B | 23.16B | 20.59B | 18.09B | 17.44B | 16.86B | 15.71B | 14.10B | 12.85B | 14.46B | 14.39B | 12.08B | 11.87B | 8.54B | 7.65B | 8.10B |
| Cost of Revenue | 11.62B | 8.89B | 10.46B | 7.81B | 7.90B | 6.57B | 6.13B | 5.73B | 6.46B | 5.74B | 5.84B | 5.04B | 4.21B | 5.23B | 4.14B | 3.56B | 3.82B | 2.82B | 2.88B | 3.65B |
| Gross Profit | 31.25B | 25.46B | 40.62B | 22.27B | 16.88B | 16.59B | 14.47B | 12.35B | 10.98B | 11.11B | 9.86B | 9.06B | 8.63B | 9.23B | 10.24B | 8.53B | 8.05B | 5.73B | 4.77B | 4.45B |
| Gross Profit Ratio | 72.90% | 74.13% | 79.52% | 74.03% | 68.12% | 71.65% | 70.24% | 68.31% | 62.96% | 65.94% | 62.80% | 64.28% | 67.20% | 63.84% | 71.21% | 70.57% | 67.78% | 67.02% | 62.33% | 54.89% |
| Research & Development | 11.23B | 8.80B | 7.18B | 5.36B | 6.00B | 4.35B | 4.21B | 4.07B | 3.35B | 3.33B | 2.20B | 1.99B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.99B | 4.89B | 4.78B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 721.00M | 1.23B | 1.14B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.49B | 11.68B | 13.51B | 8.62B | 7.64B | 7.27B | 6.47B | 5.92B | 5.48B | 5.71B | 6.12B | 5.92B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.00M | 58.00M | 38.00M | 61.00M | 4.00M | 16.00M | 10.00M | 51.69M | 107.02M | 109.73M | 26.21M | 22.70M | 24.80M | 16.12M | 128.05M | 121.70M | 248.69M | -287.86M | -199.08M | -2.33B |
| Operating Expenses | 23.72B | 20.48B | 20.69B | 14.00B | 13.64B | 11.63B | 10.68B | 9.99B | 8.83B | 9.10B | 8.32B | 7.91B | 7.54B | 7.82B | 8.24B | 7.98B | 7.77B | 5.89B | 4.80B | 3.99B |
| Cost & Expenses | 35.34B | 29.37B | 31.15B | 21.82B | 21.54B | 18.19B | 16.81B | 15.72B | 15.29B | 14.84B | 14.16B | 12.95B | 11.76B | 13.05B | 12.38B | 11.54B | 11.59B | 8.71B | 7.68B | 7.64B |
| Interest Income | 111.00M | 33.00M | 7.00M | 7.00M | 19.00M | 20.00M | 20.00M | 16.61M | 27.08M | 31.08M | 34.40M | 36.40M | 50.25M | 56.70M | 47.05M | 58.42M | 52.55M | 45.82M | 3.95M | 3.82M |
| Interest Expense | 86.00M | 44.00M | 45.00M | 42.00M | 22.00M | 21.00M | 27.00M | 28.99M | 32.67M | 38.10M | 43.55M | 50.29M | 57.51M | 58.96M | 69.05M | 62.97M | 65.15M | 58.71M | 51.59M | 49.60M |
| Depreciation & Amortization | 3.20B | 2.00B | 1.95B | 1.89B | 1.43B | 1.34B | 1.38B | 1.45B | 1.41B | 1.35B | 1.11B | 979.19M | 1.10B | 975.71M | 743.33M | 694.77M | 575.92M | 586.01M | 620.46M | 548.31M |
| EBITDA | 10.53B | 6.97B | 21.88B | 10.18B | 4.68B | 6.31B | 5.17B | 3.97B | 3.90B | 3.72B | 2.83B | 2.09B | 2.10B | 2.31B | 2.40B | 1.32B | 1.08B | 33.00M | 375.62M | -1.33B |
| EBITDA Ratio | 24.56% | 21.78% | 44.05% | 34.77% | 19.16% | 27.68% | 25.33% | 21.82% | 21.39% | 21.28% | 18.06% | 15.50% | 16.85% | 16.23% | 18.58% | 11.58% | 9.76% | 1.86% | 4.91% | -16.25% |
| Operating Income | 7.53B | 4.98B | 19.93B | 8.27B | 3.24B | 4.97B | 3.78B | 2.36B | 2.15B | 2.01B | 1.55B | 1.15B | 1.09B | 1.41B | 2.01B | 546.47M | 281.97M | -163.57M | -35.37M | 459.50M |
| Operating Income Ratio | 17.57% | 14.49% | 39.02% | 27.49% | 13.09% | 21.45% | 18.37% | 13.06% | 12.35% | 11.95% | 9.84% | 8.16% | 8.48% | 9.74% | 13.95% | 4.52% | 2.38% | -1.91% | -0.46% | 5.67% |
| Total Other Income/Expenses | -288.00M | 437.00M | -529.00M | 384.00M | 178.00M | -39.00M | 111.00M | 130.79M | 306.49M | 319.71M | 132.00M | -86.13M | -147.71M | -133.52M | -423.68M | 15.65M | 154.93M | -448.21M | 74.56M | -2.39B |
| Income Before Tax | 7.24B | 5.41B | 19.40B | 8.65B | 3.42B | 4.93B | 3.90B | 2.49B | 2.46B | 2.33B | 1.68B | 1.06B | 942.06M | 1.27B | 1.58B | 562.13M | 436.89M | -611.78M | 39.19M | -1.93B |
| Income Before Tax Ratio | 16.90% | 15.76% | 37.99% | 28.76% | 13.81% | 21.28% | 18.91% | 13.78% | 14.10% | 13.85% | 10.68% | 7.55% | 7.33% | 8.81% | 11.01% | 4.65% | 3.68% | -7.16% | 0.51% | -23.80% |
| Income Tax Expense | 1.71B | 1.63B | 4.89B | 1.76B | 742.00M | 1.22B | 825.00M | 629.52M | 669.66M | 651.89M | 381.13M | 333.95M | 308.05M | 347.51M | 279.84M | 21.20M | 34.38M | 1.14B | 68.98M | -658.99M |
| Net Income | 5.51B | 3.77B | 14.51B | 6.89B | 2.68B | 3.72B | 3.07B | 1.86B | 1.79B | 1.68B | 1.30B | 730.72M | 633.99M | 926.47M | 1.30B | 539.91M | 399.97M | -1.75B | -31.86M | -1.27B |
| Net Income Ratio | 12.85% | 10.98% | 28.40% | 22.91% | 10.81% | 16.04% | 14.91% | 10.30% | 10.26% | 9.98% | 8.25% | 5.18% | 4.94% | 6.41% | 9.06% | 4.47% | 3.37% | -20.49% | -0.42% | -15.71% |
| EPS | 44.13 | 30.34 | 117.26 | 55.80 | 21.72 | 30.17 | 24.68 | 14.74 | 14.03 | 13.21 | 10.20 | 5.76 | 4.94 | 7.23 | 12.69 | 5.02 | 3.69 | -15.96 | -0.50 | -16.38 |
| EPS Diluted | 43.92 | 30.22 | 116.79 | 55.52 | 21.59 | 29.99 | 24.53 | 14.65 | 13.95 | 13.13 | 10.13 | 5.73 | 4.92 | 7.15 | 11.39 | 5.02 | 3.69 | -15.96 | -0.50 | -16.38 |
| Weighted Avg Shares Out | 124.79M | 124.31M | 123.72M | 123.52M | 123.28M | 123.14M | 124.39M | 126.42M | 127.55M | 127.33M | 127.10M | 126.91M | 128.41M | 128.11M | 102.64M | 107.49M | 108.55M | 109.70M | 63.10M | 77.69M |
| Weighted Avg Shares Out (Dil) | 125.40M | 124.84M | 124.21M | 124.13M | 124.04M | 123.87M | 125.17M | 127.15M | 128.25M | 128.11M | 127.96M | 127.52M | 128.79M | 129.53M | 114.41M | 107.49M | 108.55M | 109.70M | 63.10M | 77.69M |
Source: https://incomestatements.info
Category: Stock Reports